Background Because studies of direct oral anticoagulants in patients with venous
thromboembolism and non-valvular atrial fibrillation have had minimal representation of …

Abstract Background The International Society on Thrombosis and Haemostasis
recommends avoiding the use of direct oral anticoagulants (DOACs) in patients with a body …

Traditionally, the management of patients with pulmonary embolism has been accomplished
with anticoagulant treatment with parenteral heparins and oral vitamin K antagonists …

This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with …

Purpose: There is limited clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …

Obesity plays an essential role in the safety of pharmacologic drugs. There is paucity of data
for direct oral anticoagulants (DOACs) in the obese, despite these agents becoming more …

Direct oral anticoagulants (DOACs, ie dabigatran, apixaban, edoxaban and rivaroxaban) are
prescribed in fixed-dose regimens to treat and prevent thrombosis. 1 The market …

Objectives: Determining whether a patient has taken a direct oral anticoagulant (DOAC) is
critical during the periprocedural and preoperative period in the emergency department …

Pulmonary embolism management has typically been accomplished with anticoagulant
treatment that includes parenteral heparins and oral vitamin K antagonists. Even though …

Background: Best practice recommendations are lacking. Thus far, literature has described
pharmacist-led DOAC monitoring. Objective: The purpose of this study is to describe a …